Flinton Capital Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Flinton Capital Management’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$139K	Hold	2,464	–	–	﹤0.01%	726
2019 Q2	$137K	Hold	2,464	–	–	﹤0.01%	738
2019 Q1	$124K	Hold	2,464	–	–	﹤0.01%	746
2018 Q4	$99K	Buy	2,464 +476	+24%	+$24.5K	﹤0.01%	750
2018 Q3	$138K	Buy	1,988 +168	+9%	+$12.7K	﹤0.01%	755
2018 Q2	$138K	Hold	1,820	–	–	﹤0.01%	717
2018 Q1	$96K	Buy	1,820 +308	+20%	+$17.9K	﹤0.01%	763
2017 Q4	$81K	Buy	1,512 +280	+23%	+$15.6K	﹤0.01%	787
2017 Q3	$73K	Buy	1,232 +364	+42%	+$22K	﹤0.01%	778
2017 Q2	$68K	Buy	868 +476	+121%	+$38.9K	﹤0.01%	768
2017 Q1	$33K	Buy	+392	New	+$29.1K	﹤0.01%	792

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Flinton Capital Management's EGRX Position: Q3 2019 in Review

Flinton Capital Management held its Eagle Pharmaceuticals, Inc. (EGRX) position steady in Q3 2019 at 2,464 shares worth $139K. The position accounts for ﹤0.01% of the portfolio, ranked #726.

Flinton Capital Management first reported a position in EGRX in Q1 2017 and has held it in 11 quarters since. 183 funds tracked by Wall St. Rank hold EGRX as of Q3 2019.

Flinton Capital Management held 2,464 shares of Eagle Pharmaceuticals, Inc. worth $139K as of Q3 2019.
Flinton Capital Management left its Eagle Pharmaceuticals, Inc. share count unchanged in Q3 2019.
Eagle Pharmaceuticals, Inc. made up ﹤0.01% of Flinton Capital Management's portfolio in Q3 2019, its #726 holding.
Flinton Capital Management first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2017 and has held it in 11 quarters since.
183 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2019.

Based on Flinton Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.